FORMATION AND LOSS OF O-6-METHYLDEOXYGUANOSINE IN HUMAN-LEUKOCYTE DNA FOLLOWING SEQUENTIAL DTIC AND FOTEMUSTINE CHEMOTHERAPY

被引:30
作者
LEE, SM
MARGISON, GP
THATCHER, N
OCONNOR, PJ
COOPER, DP
机构
[1] PATERSON INST CANC RES,CANC RES CAMPAIGN,DEPT CARCINOGENESIS,MANCHESTER M20 9BX,LANCS,ENGLAND
[2] CHRISTIE HOSP & HOLT RADIUM INST,NHS TRUST,CANC RES CAMPAIGN,DEPT MED ONCOL,MANCHESTER M20 9BX,LANCS,ENGLAND
关键词
D O I
10.1038/bjc.1994.165
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
There is increasing evidence to indicate that O-6-methyldeoxyguanosine (O-6-MedG) formation in DNA is a critical cytotoxic event following exposure to certain anti-tumour alkylating agents and that the DNA repair protein O-6-alkylguanine-DNA alkyltransferase (ATase) can confer resistance to these agents. We recently demonstrated a wide inter-individual variation in the depletion and subsequent regeneration of ATase in human peripheral blood lymphocytes following sequential DTIC (400 mg m(-2)) and fotemustine (100 mg m(-2)) treatment, with the nadir ATase activity occurring approximately 4 h after DTIC administration. We have now measured the formation and loss of O-6-methyldeoxyguanosine (O-6-MedG) in the DNA of peripheral leucocytes of eight patients receiving this treatment regimen. O-6-MedG could be detected within 1 h and maximal levels occurred approximately 3-5h after DTIC administration. Following the first treatment cycle, considerable inter-individual variation was observed in the peak O-6-MedG levels, with values ranging from 0.71 to 14.3 mu mol of O-6-MedG per mol of dG (6.41 +/- 5.53, mean +/- s.d.). Inter- and intra-individual variation in the extent of O-6-MedG formation was also seen in patients receiving additional treatment cycles. This may be a consequence of inter-patient differences in the capacity for metabolism of DTIC to release a methylating intermediate and could be one of the determinants of clinical response. Both the pretreatment ATase levels and the extent of ATase depletion were inversely correlated with the amount of O-6-MedG formed in leucocyte DNA when expressed either as peak levels (r = -0.59 and -0.75 respectively) or as the area under the concentration-time curve (r = -0.72 and -0.73 respectively). One complete and one partial clinical response were seen, and these occurred in the two patients with the highest O-6-MedG levels in the peripheral leucocyte DNA, although the true significance of this observation has yet to be established.
引用
收藏
页码:853 / 857
页数:5
相关论文
共 30 条
[1]   PROMUTAGENIC METHYLATION DAMAGE IN BLADDER DNA FROM PATIENTS WITH BLADDER-CANCER ASSOCIATED WITH SCHISTOSOMIASIS AND FROM NORMAL INDIVIDUALS [J].
BADAWI, AF ;
MOSTAFA, MH ;
ABOULAZM, T ;
HABOUBI, NY ;
OCONNOR, PJ ;
COOPER, DP .
CARCINOGENESIS, 1992, 13 (05) :877-881
[2]  
BADAWI AF, 1991, EUR J CANCER, V27, P46
[3]  
BALCH CM, 1989, CANCER PRINCIPLES PR, P1499
[4]   EXPRESSION IN MAMMALIAN-CELLS OF A TRUNCATED ESCHERICHIA-COLI GENE CODING FOR O-6-ALKYLGUANINE ALKYLTRANSFERASE REDUCES THE TOXIC EFFECTS OF ALKYLATING-AGENTS [J].
BRENNAND, J ;
MARGISON, GP .
CARCINOGENESIS, 1986, 7 (12) :2081-2084
[5]  
CATAPANO CV, 1987, CANCER RES, V47, P4884
[6]  
COMIS RL, 1976, CANCER TREAT REP, V60, P165
[7]  
DEGAN P, 1988, CANCER RES, V48, P5065
[8]   IMPORTANCE OF THE DNA-REPAIR ENZYME O-6-ALKYL GUANINE ALKYLTRANSFERASE (AT) IN CANCER-CHEMOTHERAPY [J].
DINCALCI, M ;
CITTI, L ;
TAVERNA, P ;
CATAPANO, CV .
CANCER TREATMENT REVIEWS, 1988, 15 (04) :279-292
[9]   DNA METHYL-ADDUCT DOSIMETRY AND O-6-ALKYLGUANINE-DNA ALKYL TRANSFERASE-ACTIVITY DETERMINATIONS IN RAT MAMMARY CARCINOGENESIS BY PROCARBAZINE AND N-METHYLNITROSOUREA [J].
FONG, LYY ;
JENSEN, DE ;
MAGEE, PN .
CARCINOGENESIS, 1990, 11 (03) :411-417
[10]  
FOSTER B J, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P401